CN112189849A - 一种降尿酸组合物及其制备方法 - Google Patents
一种降尿酸组合物及其制备方法 Download PDFInfo
- Publication number
- CN112189849A CN112189849A CN202011172735.4A CN202011172735A CN112189849A CN 112189849 A CN112189849 A CN 112189849A CN 202011172735 A CN202011172735 A CN 202011172735A CN 112189849 A CN112189849 A CN 112189849A
- Authority
- CN
- China
- Prior art keywords
- parts
- uric acid
- dihydromyricetin
- theanine
- resveratrol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 229940116269 uric acid Drugs 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 claims abstract description 42
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 42
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims abstract description 21
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 claims abstract description 21
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 21
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 claims abstract description 21
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 21
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims abstract description 21
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims abstract description 21
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 21
- 229940016667 resveratrol Drugs 0.000 claims abstract description 21
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 claims abstract description 21
- 229940026509 theaflavin Drugs 0.000 claims abstract description 21
- 235000014620 theaflavin Nutrition 0.000 claims abstract description 21
- 229940026510 theanine Drugs 0.000 claims abstract description 21
- 235000003599 food sweetener Nutrition 0.000 claims description 14
- 239000003765 sweetening agent Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 7
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 125000000185 sucrose group Chemical group 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 201000005569 Gout Diseases 0.000 abstract description 10
- 230000029142 excretion Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 230000000638 stimulation Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract description 3
- 108010093894 Xanthine oxidase Proteins 0.000 abstract description 3
- 102100033220 Xanthine oxidase Human genes 0.000 abstract description 3
- 150000001450 anions Chemical class 0.000 abstract description 3
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 210000001612 chondrocyte Anatomy 0.000 abstract description 3
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000002757 inflammatory effect Effects 0.000 abstract description 3
- 239000011159 matrix material Substances 0.000 abstract description 3
- 108020004999 messenger RNA Proteins 0.000 abstract description 3
- 201000008482 osteoarthritis Diseases 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 206010028391 Musculoskeletal Pain Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 11
- 238000004806 packaging method and process Methods 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 201000001431 Hyperuricemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241001260012 Bursa Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供了一种降尿酸组合物及其制备方法，涉及保健食品领域，其主要功能性成分是设定配比的茶黄素、白藜芦醇、二氢杨梅素、茶氨酸以及虫草素，该组合物主要通过抑制黄嘌呤氧化酶活性、调节相关阴离子转运体mRNA与蛋白表达水平和促进尿酸***，起到降低尿酸和抗痛风的作用；同时能够减轻IL‑1β刺激后的软骨细胞的基质降解以及降低炎症因子的表达，从而缓解骨关节炎的症状并缓解骨关节疼痛，该降尿酸的组合物具有功效显著、降尿酸明显、安全性好以及服用方便的优点，具有良好的开发应用前景。
Description
技术领域
本发明涉及保健食品领域，尤其涉及一种降尿酸组合物及其制备方法。
背景技术
痛风是一种由于嘌呤生物合成代谢增加、尿酸产生过多或因尿酸***不良而致血中尿酸升高、尿酸盐结晶沉积，从而在关节滑膜、滑囊、软骨及其他组织中引起的反复发作性炎性疾病，是成人最常见的关节炎类型之一。临床对痛风药物治疗以控制病症急性发作、纠正高尿酸与预防关节炎复发和尿酸盐沉积、保护肾脏功能等为主要目标。
目前，降尿酸的化学药物大都容易引发毒副作用，如抑制尿酸生成的药物别嘌呤醇不良反应发生率高，约2％的患者会发生过敏反应，有时可能是严重且致命的，死亡率约为20％；促进尿酸***的药物尿酸酶类药物易诱发急性痛风，约4.5％的患者会产生超敏反应，同时患者经常会产生该类药物抗体，降低疗效。
发明内容
本发明所要解决的技术问题是克服现有技术中存在的不足，提供一种降尿酸组合物及其制备方法。
本发明是通过以下技术方案予以实现：一种降尿酸组合物，包括茶黄素、白藜芦醇、二氢杨梅素、茶氨酸以及虫草素。
根据上述技术方案，优选地，按照重量份数比，包括茶黄素50-70份、白藜芦醇55-75份、二氢杨梅素50-70份、茶氨酸55-70份、虫草素50-65 份。
根据上述技术方案，优选地，还包括辅料组分110-140份、甜味剂 110-140份以及助流剂10-20份。
根据上述技术方案，优选地，按照重量份数比，包括茶黄素50份、白藜芦醇55份、二氢杨梅素50份、茶氨酸55份、虫草素50份、辅料组分120份、甜味剂110份以及助流剂10份。
根据上述技术方案，优选地，按照重量份数比，包括茶黄素60份、白藜芦醇60份、二氢杨梅素60份、茶氨酸60份、虫草素60份、辅料组分130份、甜味剂125份以及助流剂15份。
根据上述技术方案，优选地，按照重量份数比，包括茶黄素70份、白藜芦醇70份、二氢杨梅素70份、茶氨酸65份、虫草素60份、辅料组分135份、甜味剂120份以及助流剂20份。
根据上述技术方案，优选地，所述辅料组分是麦芽糊精。
根据上述技术方案，优选地，所述甜味剂是蔗糖。
根据上述技术方案，优选地，所述助流剂是硬脂酸镁。
一种降尿酸组合物的制备方法，用于制备降尿酸组合物，包括以下步骤：
(1)按照重量份数比，称取茶黄素、白藜芦醇、二氢杨梅素、茶氨酸、虫草素、辅料组分、甜味剂以及助流剂；
(2)充分混合均匀，制成降尿酸的组合物的片剂、胶囊或颗粒。
本发明的有益效果是：本发明提供了一种降尿酸组合物，进而实现预防和/或治疗高尿酸血症/痛风；该组合物的主要组分为茶黄素、白藜芦醇、二氢杨梅素、茶氨酸、虫草素，该组合物主要通过抑制黄嘌呤氧化酶活性、调节相关阴离子转运体mRNA与蛋白表达水平和促进尿酸***，起到降低尿酸和抗痛风的作用；同时减轻IL-1β刺激后的软骨细胞的基质降解以及降低炎症因子的表达，从而缓解骨关节炎的症状并缓解骨关节疼痛，具有良好的开发应用前景。
具体实施方式
下面将对发明的技术方案进行清楚、完整地描述，显然，所描述的实施例是发明一部分实施例，而不是全部的实施例。基于发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于发明保护的范围。
本发明提供了一种降尿酸组合物，包括茶黄素、白藜芦醇、二氢杨梅素、茶氨酸以及虫草素。
进一步的，包括茶黄素50-70份、白藜芦醇55-75份、二氢杨梅素50-70 份、茶氨酸55-70份、虫草素50-65份、辅料组分110-140份、甜味剂 110-140份以及助流剂10-20份，其中辅料组分优选为麦芽糊精，甜味剂优选为蔗糖，助流剂优选为硬脂酸镁。
实施例1
根据上述技术方案，优选地，按照重量份数比，包括茶黄素50份、白藜芦醇55份、二氢杨梅素50份、茶氨酸55份、虫草素50份、麦芽糊精120份、蔗糖110份以及硬脂酸镁10份。
实施例2
根据上述技术方案，优选地，按照重量份数比，包括茶黄素60份、白藜芦醇60份、二氢杨梅素60份、茶氨酸60份、虫草素60份、麦芽糊精130份、蔗糖125份以及硬脂酸镁15份。
实施例3
根据上述技术方案，优选地，按照重量份数比，包括茶黄素70份、白藜芦醇70份、二氢杨梅素70份、茶氨酸65份、虫草素60份、麦芽糊精135份、蔗糖120份以及硬脂酸镁20份。
用于制备降尿酸的组合物的制备方法，包括以下步骤：
(1)按照重量份数比，称取茶黄素、白藜芦醇、二氢杨梅素、茶氨酸、虫草素、辅料组分、甜味剂以及助流剂；
(2)充分混合均匀，制成降尿酸的组合物的片剂、胶囊或颗粒。
片剂：将上述经过效果例验证的优选配方组合(实施例1)，充分搅拌均匀，压片，采用压片机将上述成分在环境相对湿度60％以下的环境中进行压片成型以制得成品；包装，将包装袋或包装盒灭菌后进行包装封存。
胶囊：将上述经过效果例验证的优选配方组合(实施例1)，充分搅拌均匀，倒入胶囊填充模具中，灌装胶囊，抛光，分装，制得胶囊。
颗粒：将上述经过效果例验证的优选配方组合(实施例1)，充分搅拌均匀，使用浓度为50％(V/V)的乙醇作为粘合剂，制成软材，将上述软材制成颗粒，50℃沸腾干燥约40min，控制颗粒水分为5％，然后整粒，分装，制得颗粒剂。
动物实验
采用实施例3中的配方制成实验药，进行动物实验：
选择健康雄性Sprague Dawley大鼠50只，按6.5g/kg灌胃，每日两次，持续30天，未出现毒副反应；
临床资料
1、病例选择收治门诊患者100例，患者年龄在30-70岁，血尿酸(UA) 高于7.0mg/dl，临床表现：经常夜晚出现突然性的关节疼，发病急，关节部位出现严重的疼痛、水肿、红肿和炎症，疼痛感慢慢减轻直至消失，持续几天或几周不等。
2、治疗方法
服用本发明实施例制备的组合物，每次服用1剂，每天早、晚各服1 次，20天为一个疗程，连续服用3个疗程；服药期间，限制高嘌呤，高蛋白食物；忌食豆制品、菠菜、卤菜、味精、酒、醋、动物内脏、海鲜、辛辣刺激等。
3、疗效评定
结果显效：痛风性关节炎消除，身体恢复正常，观察半年后无复发；
好转：痛风性关节炎症状明显好转，身体素质明显恢复；
无效：症状无改善。
4、治疗结果
用本发明的组合物改善痛风性关节炎患者100例，结果显效72例，好转23例，无效5例，总有效率为95.0％，服药过程未观察到过敏及其它不良反应。
综上，本发明的降尿酸的组合物具有功效显著，降尿酸明显，安全性好，服用方便的优点。
本发明的有益效果是：本发明提供了一种降尿酸组合物，进而实现预防和/或治疗高尿酸血症/痛风；该组合物的主要组分为茶黄素、白藜芦醇、二氢杨梅素、茶氨酸、虫草素，该组合物主要通过抑制黄嘌呤氧化酶活性、调节相关阴离子转运体mRNA与蛋白表达水平和促进尿酸***，起到降低尿酸和抗痛风的作用；同时减轻IL-1β刺激后的软骨细胞的基质降解以及降低炎症因子的表达，从而缓解骨关节炎的症状并缓解骨关节疼痛，具有良好的开发应用前景。
最后应说明的是：以上各实施例仅用以说明发明的技术方案，而非对其限制；尽管参照前述各实施例对发明进行了详细的说明，本领域的普通技术人员应当理解：其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分或者全部技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离发明各实施例技术方案的范围。
Claims (10)
1.一种降尿酸组合物，其特征在于，包括茶黄素、白藜芦醇、二氢杨梅素、茶氨酸以及虫草素。
2.根据权利要求1所述的一种降尿酸组合物，其特征在于，按照重量份数比，包括茶黄素50-70份、白藜芦醇55-75份、二氢杨梅素50-70份、茶氨酸55-70份、虫草素50-65份。
3.根据权利要求2所述的一种降尿酸组合物，其特征在于，还包括辅料组分110-140份、甜味剂110-140份以及助流剂10-20份。
4.根据权利要求3所述的一种降尿酸组合物，其特征在于，按照重量份数比，包括茶黄素50份、白藜芦醇55份、二氢杨梅素50份、茶氨酸55份、虫草素50份、辅料组分120份、甜味剂110份以及助流剂10份。
5.根据权利要求3所述的一种降尿酸组合物，其特征在于，按照重量份数比，包括茶黄素60份、白藜芦醇60份、二氢杨梅素60份、茶氨酸60份、虫草素60份、辅料组分130份、甜味剂125份以及助流剂15份。
6.根据权利要求3所述的一种降尿酸组合物，其特征在于，按照重量份数比，包括茶黄素70份、白藜芦醇70份、二氢杨梅素70份、茶氨酸65份、虫草素60份、辅料组分135份、甜味剂120份以及助流剂20份。
7.根据权利要求4-6中任意一项所述的一种降尿酸组合物，其特征在于，所述辅料组分是麦芽糊精。
8.根据权利要求7所述的一种降尿酸组合物，其特征在于，所述甜味剂是蔗糖。
9.根据权利要求8所述的一种降尿酸组合物，其特征在于，所述助流剂是硬脂酸镁。
10.一种降尿酸组合物的制备方法，用于制备权利要求1-6中任意一项所述的降尿酸组合物，其特征在于，包括以下步骤：
(1)按照重量份数比，称取茶黄素、白藜芦醇、二氢杨梅素、茶氨酸、虫草素、辅料组分、甜味剂以及助流剂；
(2)充分混合均匀，制成降尿酸的组合物的片剂、胶囊或颗粒。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011172735.4A CN112189849A (zh) | 2020-10-28 | 2020-10-28 | 一种降尿酸组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011172735.4A CN112189849A (zh) | 2020-10-28 | 2020-10-28 | 一种降尿酸组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112189849A true CN112189849A (zh) | 2021-01-08 |
Family
ID=74012004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011172735.4A Pending CN112189849A (zh) | 2020-10-28 | 2020-10-28 | 一种降尿酸组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112189849A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114432374A (zh) * | 2022-04-12 | 2022-05-06 | 深圳德荫堂生物科技有限公司 | 一种辅助降尿酸的生物药剂及生产方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697972A (zh) * | 2012-06-08 | 2012-10-03 | 长沙玄黄生物科技有限公司 | 一种降尿酸药物 |
| CN103393783A (zh) * | 2013-07-29 | 2013-11-20 | 天津尖峰弗兰德医药科技发展有限公司 | 一种含有白藜芦醇的组合物及用途 |
| CN107898803A (zh) * | 2017-11-23 | 2018-04-13 | 广东省微生物研究所 | 虫草素在制备降尿酸药物中的应用 |
| CN108042627A (zh) * | 2017-12-28 | 2018-05-18 | 广东粤微食用菌技术有限公司 | 一种降高尿酸血症的组合物及其制备方法和用途 |
| CN110448579A (zh) * | 2019-09-10 | 2019-11-15 | 北京汉藏金生物科技有限公司 | 一种快速降尿酸配方 |
-
2020
- 2020-10-28 CN CN202011172735.4A patent/CN112189849A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697972A (zh) * | 2012-06-08 | 2012-10-03 | 长沙玄黄生物科技有限公司 | 一种降尿酸药物 |
| CN103393783A (zh) * | 2013-07-29 | 2013-11-20 | 天津尖峰弗兰德医药科技发展有限公司 | 一种含有白藜芦醇的组合物及用途 |
| CN107898803A (zh) * | 2017-11-23 | 2018-04-13 | 广东省微生物研究所 | 虫草素在制备降尿酸药物中的应用 |
| CN108042627A (zh) * | 2017-12-28 | 2018-05-18 | 广东粤微食用菌技术有限公司 | 一种降高尿酸血症的组合物及其制备方法和用途 |
| CN110448579A (zh) * | 2019-09-10 | 2019-11-15 | 北京汉藏金生物科技有限公司 | 一种快速降尿酸配方 |
Non-Patent Citations (4)
| Title |
|---|
| 刘顺;李赫宇;赵玲;: "白藜芦醇降血尿酸、抗炎作用研究进展", 药物评价研究 * |
| 卢忠英;郁建平;陈仕学;姚元勇;: "藤茶提取物中二氢杨梅素对大鼠急性痛风性关节炎模型的影响", 中国现代应用药学 * |
| 周启蒙;杜冠华;: "茶黄素降低黄嘌呤联合氧嗪酸钾诱导高尿酸血症小鼠的血浆尿酸作用及机制探究", 中国药理学与毒理学杂志 * |
| 周启蒙;赵晓悦;王海港;杨海光;宋俊科;王金华;杜冠华;: "茶黄素降低高尿酸血症小鼠血清尿酸的作用与机制探究", 中国新药杂志 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114432374A (zh) * | 2022-04-12 | 2022-05-06 | 深圳德荫堂生物科技有限公司 | 一种辅助降尿酸的生物药剂及生产方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
| JP5498521B2 (ja) | 放射線障害軽減剤 | |
| CA2274510C (en) | Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine | |
| CN102885857A (zh) | 治疗消化道溃疡用的美洲大蠊提取物的提取方法 | |
| US7834056B2 (en) | Pharmaceutical composition for gout | |
| WO1998025631A9 (en) | Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine | |
| KR20000070733A (ko) | 위장 리파아제 억제제의 용도 | |
| CN102711774A (zh) | 含有高水溶性2-羟丙基-β-环糊精作为有效成分的肥胖疾病预防及治疗用组合物 | |
| CN112189849A (zh) | 一种降尿酸组合物及其制备方法 | |
| US3958004A (en) | Phenoxyacetic acid derivatives as uricosuric agents | |
| CN106074463A (zh) | ***二酚在制备治疗痛风性关节炎药物中的应用 | |
| CA2442410A1 (en) | Duloxetine for treatment of hot flashes | |
| CN110314233B (zh) | 包含柠檬苦素类化合物和dpp-4抑制剂的组合产品 | |
| BR112020018362A2 (pt) | Composição de glp-1 para tratar obesidade e controle de peso | |
| JP3634721B2 (ja) | 高脂血症の予防又は治療剤 | |
| RU2670612C9 (ru) | Композиция для предупреждения или лечения ожирения, содержащая α-липоевую кислоту и N-ацетилцистеин в качестве активных ингредиентов | |
| CN110279866B (zh) | 包含柠檬苦素类化合物和噻唑烷二酮类药物的组合产品 | |
| KR100732614B1 (ko) | 복어 추출물을 포함하는 비만 또는 당뇨성 질환의 예방또는 치료용 약학 조성물 | |
| CN112716969A (zh) | 治疗阿尔茨海默症的组合物及其制备方法、应用 | |
| US20040152733A1 (en) | Duloxetine for treatment of hot flashes | |
| CN105878263B (zh) | 含有苹果酸氯波必利的药物组合物及其应用 | |
| CN112641776A (zh) | 一种以二甲双胍或其可药用盐和澳格列汀或其可药用盐为活性成分的药用组合物 | |
| EA028995B1 (ru) | Соль тезофензина и оптически активных ацетиламинокислот, их применение для лечения и/или профилактики нарушений, связанных с ожирением | |
| CN106074540B (zh) | 一种用于高尿酸血症治疗的药物组合物及其应用 | |
| WO1995010292A1 (en) | Diabetes treatment and prophylaxis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210108 |